

Hans Lassmann - CV

Personal Data

Date of Birth: July 7, 1949
Place of Birth: Vienna
Nationality: Austria

Education

1967-1968 Military service
1968-1975 Medical School, University of Vienna, Austria (MD)
1975-1983 Training in clinical and experimental neuropathology, Institute of Neurology, University of Vienna

Career History

1977-1978 Post Doc; IBR, New York; (Prof. H. Wosniewski)
1983 Habilitation; Neuropathology; Univ. Vienna
1983-1990 Head Research Group for Experimental Neuropathology, Institute of Neurology, University of Vienna
1990-1995 Head Research Unit for Experimental Neuropathology, Austrian Academy of Sciences
1993 a.o. Univ. Prof. For Experimental Neuropathology, Univ. Vienna
1999 o. Univ. Prof. For Neuroimmunology; Brain Research Institute, University of Vienna
1999-2007 Acting Director, Center for Brain Research, Medical University of Vienna
2005 Corresponding Member, Austrian Academy of Sciences

Awards

2000 Highly Cites Researcher in ISI Highly Cited Researchers Project
Forschungspreis der SOBEEK Foundation for outstanding Research in Multiple Sclerosis
2005 Charcot Award of the International Federation of MS Societies for Lif Long Achievements in Multiple Sclerosis Research

Publications:

330 original publications; 50 reviews/book chapters; > 200 invited lectures

Teaching activities (PhD students of the last 5 years outside of CCHD)

Name of the student	Sex	Research topic	Title of the thesis	No of publications
Alexandra Jutzelnigg *	f	MS	Cortical Lesions in MS	5
Assunta Dal Bianco*	f	MS	MS and Alzheimer's Disease	1
Peter Patrikios	m	MS	Remyelination in MS	1
Christina Marik	f	MS	Innate immunity in MS lesions	1

*These students were not enrolled in an official PhD program, since that was not existing at this time

Externally funded national and international projects (last 5 years)

Funding organisation	project No.	Research topic of the project	Amount in k€
MUV	UE10207001	CCHD	147
FWF	W1205	CCHD	147
EU-Integrated Project Neuropsise	PL 018637	Neuroprotective Strategies in MS	426
FWF	P 19854 B2	Innate Immunity in Initial MS lesions	206
WFL	AU-001/07	Microglia diversity	70
NMSS	RG-3185-07	The MS lesion project	36

10 most relevant papers of the last 5 years

Dal Bianco A, Bradl M, Frischer J, Kutzelnigg A, Jellinger K, **Lassmann H** (2008) Multiple sclerosis and Alzheimer's disease *Ann Neurol*, **63(2)**: 174-183

Mahad D, Ziabreva I, **Lassmann H**, Turnbull D (2008) Mitochondrial defects in acute multiple sclerosis lesions. *Brain*, **131(Pt 7)**: 1722-1735

Marik C, Felts PA, Bauer J, **Lassmann H**, Smith KJ. (2007) Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? *Brain*. 2007 Nov; **130(Pt 11)**:2800-2815

Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Bruck W, Lucchinetti C, **Lassmann H** (2006) Remyelination is extensive in a subset of multiple sclerosis patients. *Brain* **129 (Pt. 12)**:3165-3172

Stadelmann C, Ludwin S, Tabira T, Guseo A, Lucchinetti CF, Leel-Ossy L, Ordinario AT, Bruck W, **Lassmann H** (2005) Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis. *Brain* **128(Pt 5)**:979-987

Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, **Lassmann H** (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. *Brain*. **128(Pt 11)**:2705-2712

Stadelmann C, Kerschensteiner M, Misgeld T, Bruck W, Hohlfeld R, **Lassmann H** (2002) BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? *Brain* **125**:75-85

Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, **Lassmann H** (2002) A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. *Brain* **125**:1450-1461

Kornek B, Storch M, Weissert R, Wallstroem E, Stefferl A, Olsson T, Linington C, Schmidbauer M, **Lassmann H** (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive and remyelinated lesions. *Amer J Pathol* **157**:267-276

Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, **Lassmann H** (2000) Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. *Ann Neurol* **47**:707-717

Additional References

Adams RA, Bauer J, Flick MJ, Sikorski SL, Nuriel T, **Lassmann H**, Degen JL, Akassoglou K. (2007) The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. *J Exp Med*. 2007 Mar 19; **204(3)**:571-582

Keegan M, Konig F, McClelland R, Bruck W, Morales Y, Bitsch A, Panitch H, **Lassmann H**, Weinshenker B, Rodriguez M, Parisi J, Lucchinetti CF (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. *Lancet*. **366(9485)**:579-582

Linker RA, Maurer M, Gaupp S, Martini R, Holtmann B, Giess R, Rieckmann P, **Lassmann H**, Toyka KV, Sendtner M, Gold R (2002) CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. *Nat Med*. **8(6)**:620-624

Flugel A, Berkowicz T, Ritter T, Labeur M, Jenne DE, Li Z, Ellwart JW, Willem M, **Lassmann H**, Wekerle H (2001) Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. *Immunity* **14**:547-560

Babbe H, Roers A, Waisman A, **Lassmann H**, Goebels N, Hohlfeld R, Friese M, Schroder R, Deckert M, Schmidt S, Ravid R, Rajewsky K (2000) Clonal expansion of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. *J Exp Med* **192**:393-404

Dewey RA, Morrissey G, Coswill CM, Stone D, Bolognami F, Dodd NJF, Southgate TD, Klatzmann D, **Lassmann H**, Castro MG, Löwenstein PR (1999) Chronic brain inflammation and persistent HSV1-TK expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials. *Nature Med* **5**:1256-1263